Minimal residual disease following allogeneic hematopoietic stem cell transplantation
Nicolaus Kröger1, Koichi Miyamura, Michael R Bishop
1University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Minimal residual disease (MRD), both before and after transplantation, is a clinically important yet relatively poorly defined aspect of allogeneic hematopoietic stem cell transplantation (alloHSCT). The clinical relevance of MRD in the context of alloHSCT has been demonstrated by its association with the development of clinical relapse. However, with the possible exception of chronic myeloid leukemia (CML), the specific techniques, timing, frequency, and clinical utility, relative to improvement in patient outcomes, for monitoring MRD in the setting of alloHSCT has yet to be clearly defined. A concise overview of monitoring techniques for detecting MRD, as well as treatment strategies and biological and clinical research initiatives for MRD suggested by the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation, is covered in this article.
Insights
Minimal residual disease (MRD) monitoring after allogeneic stem cell transplantation is crucial for predicting relapse. Standardized techniques and clear clinical utility are needed to improve patient outcomes in this setting.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Minimal residual disease (MRD) is a significant factor in allogeneic hematopoietic stem cell transplantation (alloHSCT).
- The association between MRD and clinical relapse post-transplant is established.
- However, optimal MRD monitoring strategies in alloHSCT lack clear definition.
Purpose of the Study:
- To provide an overview of MRD monitoring techniques in alloHSCT.
- To discuss treatment strategies for MRD.
- To highlight research initiatives for MRD in alloHSCT.
Main Methods:
- Review of current MRD detection techniques.
- Discussion of treatment approaches based on MRD status.
- Summary of recommendations from the National Cancer Institute workshop.
Main Results:
- MRD monitoring is clinically relevant for predicting relapse after alloHSCT.
- Standardized methods, timing, and frequency for MRD assessment are not yet universally defined.
- The clinical utility of MRD monitoring for improving patient outcomes requires further clarification.
Conclusions:
- Further research and standardization are essential for optimizing MRD monitoring in alloHSCT.
- Defining the role of MRD in guiding treatment decisions is critical.
- The development of novel strategies is needed to address MRD and prevent relapse.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:19Multipotency of Hematopoietic Stem Cells